New biotech arrival gains $10M in venture funds

Fresh from announcing the move of its headquarters from France to Waltham, MA, EyeGate Pharma says it has garnered $10 million in its second round of venture financing. Innoven Partenaires and Ventech, both based in Paris, led the round. EyeGate is researching new drug/device therapies for macular degeneration and other eye diseases.

"At our new operations in Waltham, MA, we are already setting up the necessary infrastructure and developing a top-notch veteran R&D team with unique ocular delivery expertise from EyeTech (now OSI), which closed its local operations," said CEO Stephen From.

- here's the release on EyeGate